Advancing apoptosis

A RMB500 million ($72 million) series B round will enable Ascentage Pharma Group Corp. Ltd. to generate clinical proof-of-concept data for two to three cancer candidates in three years.

Future Industry Investment Fund led the round, which closed on Dec. 27. New investors Shiyu Capital, Hidragon Capital and Founder KIP Capital and existing investors YuanMing Capital, Oriza Venture Fund and EFung Capital also participated. ...